Phase I studies of imatinib mesylate combined with cisplatin and irinotecan in patients with small cell lung carcinoma

Medicine and Dentistry

• Imatinib 100%
• Irinotecan 80%
• Cisplatin 60%
• Patient 60%
• Small Cell Lung Cancer 40%
• Specimen 30%
• Neutropenia 20%
• In Vitro 20%
• Clearance 20%
• Diarrhea 20%
• Incidence 20%
• Diseases 10%
• Neoplasm 10%
• Metabolism 10%
• Toxicity 10%
• Carcinoma Cell 10%
• Combination Therapy 10%
• Granulocyte Colony Stimulating Factor 10%
• Progressive Disease 10%
• Cell Cycle Arrest 10%
• Ligand 10%
• Thrombosis 10%
• Cell Growth 10%
• Phosphotransferase 10%
• Chemotherapeutic Agent 10%
• Platelet Derived Growth Factor Receptor 10%
• Stem Cell Factor 10%
• Drug 10%
• Drug Interaction 10%
• Lung Small Cell Carcinoma Cell Line 10%
• Analysis 10%
• Inpatient 10%
• Therapeutic Procedure 10%
• Biopsy 10%
• Blood 10%

INIS

• patients 70%
• lung cells 50%
• doses 50%
• carcinomas 50%
• drugs 20%
• in vitro 20%
• diseases 20%
• clearance 20%
• diarrhea 20%
• tumors 10%
• growth 10%
• therapy 10%
• interactions 10%
• stem cells 10%
• growth factors 10%
• biopsy 10%
• receptors 10%
• kinases 10%
• toxicity 10%
• ligands 10%
• blood 10%
• cell cycle 10%
• colonies 10%
• granulocytes 10%
• metabolic pathways 10%
• thrombosis 10%

Pharmacology, Toxicology and Pharmaceutical Science

• Imatinib 100%
• Irinotecan 80%
• Cisplatin 60%
• Small Cell Lung Cancer 40%
• Neutropenia 20%
• Diarrhea 20%
• Incidence 20%
• Diseases 10%
• Toxicity 10%
• Neoplasm 10%
• Maximum Tolerated Dose 10%
• Ligand 10%
• Thrombosis 10%
• Pharmacokinetic Parameter 10%
• Phosphotransferase 10%
• Drug Interaction 10%
• Granulocyte Colony Stimulating Factor 10%
• Platelet Derived Growth Factor Receptor 10%
• Stem Cell Factor 10%
• Drug 10%